Received Sep 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
received the first dose of Twinrix on 28 Feb 2025 and the second dose was given 01 Jun 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 22-year-old female patient who received HAB (Twinrix) for prophylaxis. Previously administered products included Twinrix (received the first dose of Twinrix on 28 Feb 2025). On 01-JUN-2025, the patient received the 2nd dose of Twinrix. On 01-JUN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: received the first dose of Twinrix on 28 Feb 2025 and the second dose was given 01 Jun 2025). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-AUG-2025 Pharmacist reported that a patient received the first dose of Twinrix on 28 Feb 2025 and the second dose was given 01 Jun 2025 which led to Drug dose administration interval too long.